- Company Continuing EC1169 Program in Taxane-Exposed Patients, but Ending Clinical Development of EC1456 and of EC1169 in Taxane-Naïve Patients - - Refocusing Efforts on Chimeric Antigen Receptor ...
WEST LAFAYETTE, Ind. - Officials at Endocyte Inc., a cancer drug discovery and development company, announced Tuesday (Oct. 27, 2009) that the company has been awarded a patent from the U.S. Patent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results